

**AUROBINDO PHARMA LIMITED**  
(CIN - L24239TG1986PLC015190)

Regd Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India  
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In Lakhs)

**PART I STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2014**

Particulars	Stand alone				Consolidated			
	Three months ended		Year Ended		Three months ended		Year Ended	
	30.06.2014	31.03.2014	30.06.2013	31.03.2014	30.06.2014	31.03.2014	30.06.2013	31.03.2014
<b>1 Income from operations</b>								
(a) Net sales/income from operations (Net of excise duty)	193,456	197,926	159,578	704,957	289,461	230,588	169,960	803,848
(b) Other operating income	1,644	2,376	1,596	6,114	1,646	2,393	1,596	6,131
<b>Total income from operations (net)</b>	195,100	200,302	161,174	711,071	291,107	232,981	171,556	809,979
<b>2 Expenses</b>								
(a) Cost of material consumed	91,385	93,809	79,559	342,234	95,351	98,153	78,693	352,306
(b) Purchase of stock-in-trade	548	952	1,884	9,689	46,299	1,331	5,173	18,497
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(603)	(6,440)	5,658	(3,575)	(3,587)	(9,702)	5,262	(10,200)
(d) Employee benefits expense	14,800	13,763	12,346	51,420	30,837	23,362	18,891	83,192
(e) Depreciation and amortisation expense	6,340	4,582	4,593	18,597	9,083	8,802	7,192	31,253
(f) Provision for decline in the value of long-term investment	30,171	31,207	24,901	110,955	56,392	45,542	32,766	152,903
(g) Other expenses	142,641	143,773	128,941	537,720	234,375	167,488	147,977	627,951
<b>Total expenses</b>	52,459	56,529	32,233	173,351	56,732	65,493	23,579	182,028
<b>3 Profit/(loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)</b>	142,641	143,773	128,941	537,720	234,375	167,488	147,977	627,951
4 Other income	569	1,482	287	3,287	1,081	1,065	392	2,324
<b>5 Profit/(loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)</b>	53,028	58,011	32,520	176,638	57,813	66,558	23,971	184,352
6 Finance costs (refer note 6)	1,385	2,875	2,073	8,662	1,885	3,423	2,539	10,794
7 Foreign exchange (Gain)/Loss: (refer note 6)	(647)	(3,741)	13,953	16,029	(142)	(3,556)	17,241	20,306
<b>8 Profit/(loss) from ordinary activities after finance costs but before exceptional items (5-6-7)</b>	52,290	58,877	16,494	151,947	56,070	66,691	4,191	153,252
9 Exceptional item								
<b>10 Profit/(loss) from ordinary activities before tax (8-9)</b>	52,290	58,877	16,494	151,947	56,070	66,691	4,191	153,252
11 Tax expense/(credit)	12,950	15,817	2,131	34,738	14,643	16,528	2,445	36,345
<b>12 Net Profit/(loss) for the period (10-11)</b>	39,340	43,060	14,363	117,209	41,427	50,163	1,746	116,907
13 Minority interest					(116)	(18)	(114)	(378)
<b>14 Net Profit/(loss) after taxes and minority interest (12-13)</b>	39,340	43,060	14,363	117,209	41,543	50,181	1,860	117,285
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	2,915	2,915	2,912	2,915	2,915	2,915	2,915	2,915
16 Reserves excluding Revaluation Reserve	13,50	14,78	4,93	40,24	14,25	17,23	0,64	40,27
17 Earnings per share of Re. 1/- each (not annualised)	13.48	14.77	4.93	40.20	14.24	17.21	0.64	40.22
(a) Diluted								



## SELECT INFORMATION FOR THE QUARTER &amp; YEAR ENDED 30.06.2014

Particulars	Three months ended			Year Ended
	30.06.2014	31.03.2014	30.06.2013	
<b>A</b>				
<b>1 PARTICULARS OF SHAREHOLDING</b>				
<b>1 Public Shareholding</b>				
- Number of Shares	133,081,235	132,281,235	131,514,694	132,281,235
- Percentage of Shareholding	45.66	45.39	45.16	45.39
<b>2 Promoters and promoter group Shareholding</b>				
<b>a) Pledged/Encumbered</b>				
- Number of Shares	21,882,297	29,856,797	30,005,297	29,856,797
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	13.82	18.76	18.79	18.76
- Percentage of Shares (as a % of the total share capital of the company)	7.51	10.24	10.30	10.24
<b>b) Non-encumbered</b>				
- Number of Shares	136,493,489	129,318,989	129,691,299	129,318,989
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	86.18	81.24	81.21	81.24
- Percentage of Shares (as a % of the total share capital of the company)	46.83	44.37	44.54	44.37

Particulars	Three months ended
	30.06.2014
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	49
Disposed of during the quarter	47
Remaining unresolved at the end of the quarter	2





**NOTES:**

- 1 The above unaudited financial results for the quarter ended June 30, 2014 as reviewed by the Audit Committee have been approved by the Board at its meeting held on August 07, 2014. A Limited Review of the stand alone financial results for the quarter ended June 30, 2014 has been carried out by the Statutory Auditors.
- 2 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Venture.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs.159,782 lakhs(Quarter ended June 30, 2013: Rs. 126,586 lakhs).
- 5 Net sales for the current year include dossier income in standalone of Rs.66 lakhs (June 30, 2013:Rs. 238 lakhs) and in consolidated of Rs. 184 lakhs (June 30, 2013:Rs. 298 lakhs).
- 6 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.1,049 lakhs, Rs.5,058 lakhs, Rs.5,048, for three months ended June 30, 2014, March 31, 2014, and June 30, 2013 respectively and Rs.20,222 lakhs for the year ended March 31,2014 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 7 During the quarter, Agile Pharma B.V-Netherlands, a step down subsidiary of the Company has acquired select Western European business of Actavis. The above consolidated results for the current quarter ended June 30, 2014 includes the results of the operation of the above business of Actavis from April 1, 2014. The corresponding figures for the previous periods are not comparable.
- 8 The Board of Directors at their meeting held on September 13, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- 9 During the current quarter, pursuant to the requirements of Schedule II to the Companies Act, 2013, the management of the Company has reassessed the useful lives of fixed assets held as at April 1, 2014. Based on such internal technical reassessment, the Company has accounted for additional depreciation amounting to Rs.1,723 lakhs and Rs. 1,713 lakhs in standalone and consolidated results respectively for the current quarter. Further based on transitional provisions provided in note 7(b) of the Schedule II, an amount of Rs. 1,857 lakhs (net of deferred tax) has been adjusted with stand alone and consolidated opening retained earnings.
- 10 The figures of quarter ended March 31, 2014 are the balancing figures between audited figures in respect of the full financial year ended March 31st and unaudited published year to date figures up to the third quarter ended December 31st. The unaudited consolidated results published year to date figures up to the third quarter ended December 31st were not subject to limited review and the unaudited standalone results were subject to limited review.
- 11 The Board has approved an interim dividend @150% i.e. Rs.1.50 (Rupee one and paise fifty only) per equity share of Re 1/- (Rupee One only) for the year 2014-15.
- 12 Previous period/year figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan  
Managing Director



Place: Hyderabad  
Date: August 7, 2014

www.aurobindo.com